AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RECCE PHARMACEUTICALS LTD

0.570

0.000

Volume:30.86K

Turnover:17.34K

Market Cap:164.83M

PE:-6.30

High:0.575

Open:0.570

Low:0.555

Close:0.570

52wk High:0.730

52wk Low:0.275

Shares:289.18M

Float Shares:168.89M

Volume Ratio:1.37

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.090

EPS(LYR):-0.090

ROE:-1277.62%

ROA:-135.80%

PB:-54.01

PE(LYR):-6.30

Loading ...

Overview Company News Filings

Recce Pharmaceuticals Ltd-Change of Director's Interest Notices (X5)

THOMSON REUTERS

BUZZ-Australia's Reece Pharmaceuticals rises on research and development deal with US Army

BRIEF-Recce Pharmaceuticals Enters Second U.S. Department Of Defense Research And Development Agreement

Recce Pharmaceuticals Enters Into Research Agreement With US Army Institute of Surgical Research

MT Newswires Live

Recce Pharmaceuticals Ltd-Recce Enters Second U.S. Department of Defense R&D Agreement

THOMSON REUTERS

Retail investors invested in Recce Pharmaceuticals Ltd (ASX:RCE) copped the brunt of last week's AU$29m market cap decline

Simply Wall St.

BUZZ-Australia's Recce Pharmaceutical hits over 2-yr high on $3.5 million R&D tax rebate

Tencent Cloud Announces Strategic Partnership with Thailand's Leading Digital Asset Exchange Bitkub

BRIEF-Recce Pharmaceuticals Awarded Ausindustry Advanced Overseas Finding For Up To A$85M

BUZZ-Australia's Recce Pharmaceuticals hits 1-week high on $56.5 mln R&D boost

Recce Pharmaceuticals Ltd - Awarded Ausindustry Advanced Overseas (R&D) Finding for up to a$85M

THOMSON REUTERS

Insiders Of Recce Pharmaceuticals Are Up 73% On Their AU$6.19m Purchase

Simply Wall St.

Recce Pharmaceuticals Secures Family 4 Patent for Anti-Infectives in Hong Kong, Shares Jump 6%

MT Newswires Live

Recce Pharmaceuticals Says Hospital/Ventilator-Acquired Pneumonia Study in Mice Shows Antibacterial Activity of R327 Therapy Candidate

MT Newswires Live

Recce Receives 'First Strike' Against Remuneration Report; Shares Up 3%

MT Newswires Live

Recce Pharmaceuticals Commences Phase 3 Trial of Topical Gel for Diabetic Foot Infections

BRIEF-Recce Pharmaceuticals Reports FY Net Loss Attributable A$21.4 Million

Recce Pharmaceuticals Ltd - FY Net Loss Attributable a$21.4 Mln

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RCE.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RCE.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RCE.AU\",,,,,undefined,":{"symbol":"RCE.AU","market":"AU","secType":"STK","nameCN":"RECCE PHARMACEUTICALS LTD","latestPrice":0.57,"timestamp":1771909920000,"preClose":0.57,"halted":0,"volume":30860,"delay":0,"changeRate":0,"nameEN":"RECCE PHARMACEUTICALS LTD","floatShares":168893037,"shares":289183422,"eps":-0.090423,"marketStatus":"Not Yet Opened","change":0,"latestTime":"02-24 16:12:00 AEDT","open":0.57,"high":0.575,"low":0.555,"amount":17339,"amplitude":0.035088,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.090423,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1771974000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.57,"openAndCloseTimeList":[[1771887600000,1771909200000]],"volumeRatio":1.3703861666687245,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RCE.AU\",,,,,undefined,":{"symbol":"RCE.AU","floatShares":168893037,"roa":"-135.80%","roe":"-1277.62%","lyrEps":-0.090423,"volumeRatio":1.3703861666687245,"shares":289183422,"dividePrice":0,"high":0.575,"amplitude":0.035088,"preClose":0.57,"low":0.555,"week52Low":0.275,"pbRate":"-54.01","psRate":"21.95","week52High":0.73,"institutionHeld":0,"latestPrice":0.57,"eps":-0.090423,"divideRate":0,"volume":30860,"delay":0,"ttmEps":-0.090423,"open":0.57,"prevYearClose":0.65,"prevWeekClose":0.575,"prevMonthClose":0.56,"prevQuarterClose":0.65,"fiveDayClose":0.59,"twentyDayClose":0.655,"sixtyDayClose":0.43,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RCE.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-04-15","symbol":"RCE.AU","defaultRemindTime":1744675200000,"type":"split","dateTimestamp":1744639200000,"forFactor":990476,"toFactor":1000000,"ratio":0.990476}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RCE.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RCE.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613762992","title":"Recce Pharmaceuticals Ltd-Change of Director's Interest Notices (X5)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613762992","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613762992?lang=en_us&edition=fundamental","pubTime":"2026-02-24 14:51","pubTimestamp":1771915900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUE2QB63D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2608883145","title":"BUZZ-Australia's Reece Pharmaceuticals rises on research and development deal with US Army","url":"https://stock-news.laohu8.com/highlight/detail?id=2608883145","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608883145?lang=en_us&edition=fundamental","pubTime":"2026-02-02 12:14","pubTimestamp":1770005675,"startTime":"0","endTime":"0","summary":"BUZZ-Australia'sReece Pharmaceuticals rises on research and development deal with US Army** Shares of Australia's Recce Pharmaceuticals RCE.AX rise as much as 8.9% to A$0.61 ** Stock on track for its best session since December 3, 2025, if gains hold** Stock saps a four-session losing streak, and last up 3.6%** The pharmaceutical co signs a second cooperative research and development agreement with the U.S. Army Institute of Surgical Research** Agreement to conduct study to evaluate effectiveness of RECCE 327 gel in reducing bioburden burn wounds** Stock is down 10.8%, YTD   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nL6N3YY09C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2608833153","title":"BRIEF-Recce Pharmaceuticals Enters Second U.S. Department Of Defense Research And Development Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2608833153","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608833153?lang=en_us&edition=fundamental","pubTime":"2026-02-02 09:56","pubTimestamp":1769997414,"startTime":"0","endTime":"0","summary":"BRIEF-Recce Pharmaceuticals Enters Second U.S. Department Of Defense Research And Development AgreementFeb 2  - Recce Pharmaceuticals Ltd RCE.AX:RECCE ENTERS SECOND U.S. DEPARTMENT OF DEFENSE RESEARCH AND DEVELOPMENT AGREEMENTAGREEMENT TO ADVANCE RECCE 327 GEL FOR BURN WOUNDSFurther company coverage: RCE.AX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUE8F1KGW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2608882648","title":"Recce Pharmaceuticals Enters Into Research Agreement With US Army Institute of Surgical Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2608882648","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608882648?lang=en_us&edition=fundamental","pubTime":"2026-02-02 07:06","pubTimestamp":1769987208,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  entered into a cooperative research and development agreement with the United States Army Institute of Surgical Research to evaluate its RECCE 327 gel therapy candidate in their validated Walker-Mason rat model of burn wound infection, according to a Monday Australian bourse filing.The study will evaluate whether the gel can significantly reduce bacterial burden in infected burn wounds against methicillin-resistant bacterial pathogens, Staphylococcus aureus and Pseudomonas aeruginosa.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2608884999","title":"Recce Pharmaceuticals Ltd-Recce Enters Second U.S. Department of Defense R&D Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2608884999","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608884999?lang=en_us&edition=fundamental","pubTime":"2026-02-02 05:58","pubTimestamp":1769983121,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260201:nTUE8F1KGW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2607073491","title":"Retail investors invested in Recce Pharmaceuticals Ltd (ASX:RCE) copped the brunt of last week's AU$29m market cap decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2607073491","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607073491?lang=en_us&edition=fundamental","pubTime":"2026-01-31 07:16","pubTimestamp":1769814984,"startTime":"0","endTime":"0","summary":"Key Insights Significant control over Recce Pharmaceuticals by retail investors implies that the general public has...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rce/recce-pharmaceuticals-shares/news/retail-investors-invested-in-recce-pharmaceuticals-ltd-asxrc","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rce/recce-pharmaceuticals-shares/news/retail-investors-invested-in-recce-pharmaceuticals-ltd-asxrc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2603466670","title":"BUZZ-Australia's Recce Pharmaceutical hits over 2-yr high on $3.5 million R&D tax rebate","url":"https://stock-news.laohu8.com/highlight/detail?id=2603466670","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603466670?lang=en_us&edition=fundamental","pubTime":"2026-01-14 12:51","pubTimestamp":1768366268,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Recce Pharmaceutical hits over 2-yr high on $3.5 million R&D tax rebate** Shares of Recce Pharmaceuticals RCE.AX rise 3% to A$0.69, their highest level since early Sept 2023** Pharmac","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nL4N3YF0DP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2592962266","title":"Tencent Cloud Announces Strategic Partnership with Thailand's Leading Digital Asset Exchange Bitkub","url":"https://stock-news.laohu8.com/highlight/detail?id=2592962266","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592962266?lang=en_us&edition=fundamental","pubTime":"2025-12-17 15:44","pubTimestamp":1765957440,"startTime":"0","endTime":"0","summary":"HONG KONG, Dec. 17, 2025 /PRNewswire/ -- Tencent Cloud, the cloud business of global technology companyTencent, today announced its strategic partnership with Bitkub Group, Thailand's largest digital asset and blockchain leader, composed of companies such as; Bitkub Exchange, Thailand's leading digital asset exchange with over 90% of transaction volume in the local market, Bitkub Academy, the national hub for digital assets, Bitkub Blockchain Technology, the top blockchain infrastructure, and more. Leveraging Tencent Cloud's robust infrastructure, database technologies and AI capabilities, the collaboration will enable Bitkub to deliver secure, reliable, and scalable services for users buying, selling, and storing digital assets.Jimmy Chen, Vice President of Tencent Cloud, Vice President of APAC, Tencent Cloud International, said, \"This partnership highlights Tencent Cloud's solid commitment to delivering cutting-edge cloud infrastructure and advanced technologies specifically designed","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2847347/Tencent_Cloud_Announces_Strategic_Partnership_Thailand_s_Leading_Digital_Asset_Exchange.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2847347/Tencent_Cloud_Announces_Strategic_Partnership_Thailand_s_Leading_Digital_Asset_Exchange.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/tencent-cloud-announces-strategic-partnership-with-thailands-leading-digital-asset-exchange-bitkub-302644441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823417653.USD","LU0861579265.USD","GB00B4LPDJ14.GBP","IE00BYQQ9H92.USD","TCHmain","LU0345774391.USD","IE00B5TLWC47.USD","LU1221951129.SGD","RCE.AU","LU0690374615.EUR","LU1934455863.HKD","LU0545562505.USD","LU1037948541.HKD","LU1228905037.USD","LU1934455194.USD","LU1196500208.SGD","LU1236620834.HKD","LU2506951875.HKD","BK4588","LU0823417737.USD","IE00BFXG0V08.USD","LU0950375773.USD","GB00B4QBRK32.GBP","LU2506951958.HKD","LU0345774631.USD","LU1032955483.USD","BK4585","BK4528","LU0965508806.USD","BK4613","LU2404859667.USD","LU2506952097.USD","LU2506952170.USD","LU1236620750.USD","BK4106","ADP","LU0289941410.SGD","LU0965509010.AUD","LU1691799644.USD","LU0965509283.SGD","LU1228905540.USD","LU1934455277.USD","BK7096","LU0965509101.SGD","AI","LU1037948897.HKD","BK4130","LU0690374961.EUR","LU2404859741.USD","LU1221951046.USD"],"gpt_icon":1},{"id":"2591675485","title":"BRIEF-Recce Pharmaceuticals Awarded Ausindustry Advanced Overseas Finding For Up To A$85M","url":"https://stock-news.laohu8.com/highlight/detail?id=2591675485","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591675485?lang=en_us&edition=fundamental","pubTime":"2025-12-16 09:07","pubTimestamp":1765847232,"startTime":"0","endTime":"0","summary":"BRIEF-Recce Pharmaceuticals Awarded Ausindustry Advanced Overseas Finding For Up To A$85MDec 16  - Recce Pharmaceuticals Ltd RCE.AX:AWARDED AUSINDUSTRY ADVANCED OVERSEAS  FINDING FOR UP TO A$85MFurther company coverage: RCE.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nFWN3XL110:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2591367822","title":"BUZZ-Australia's Recce Pharmaceuticals hits 1-week high on $56.5 mln R&D boost","url":"https://stock-news.laohu8.com/highlight/detail?id=2591367822","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591367822?lang=en_us&edition=fundamental","pubTime":"2025-12-16 08:11","pubTimestamp":1765843869,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Recce Pharmaceuticals hits 1-week high on $56.5 mln R&D boost** Shares of Australia's Recce Pharmaceuticals RCE.AX rise as much as 3.3%, their highest since December 8** The pharmaceu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nL6N3XM00P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2591062776","title":"Recce Pharmaceuticals Ltd -  Awarded Ausindustry Advanced Overseas (R&D) Finding for up to a$85M","url":"https://stock-news.laohu8.com/highlight/detail?id=2591062776","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591062776?lang=en_us&edition=fundamental","pubTime":"2025-12-16 06:49","pubTimestamp":1765838949,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL110:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2587179853","title":"Insiders Of Recce Pharmaceuticals Are Up 73% On Their AU$6.19m Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2587179853","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587179853?lang=en_us&edition=fundamental","pubTime":"2025-11-30 06:00","pubTimestamp":1764453625,"startTime":"0","endTime":"0","summary":"Last week, Recce Pharmaceuticals Ltd ( ASX:RCE ) insiders, who had purchased shares in the previous 12 months were...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rce/recce-pharmaceuticals-shares/news/insiders-of-recce-pharmaceuticals-are-up-73-on-their-au619m","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rce/recce-pharmaceuticals-shares/news/insiders-of-recce-pharmaceuticals-are-up-73-on-their-au619m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2586297769","title":"Recce Pharmaceuticals Secures Family 4 Patent for Anti-Infectives in Hong Kong, Shares Jump 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586297769","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586297769?lang=en_us&edition=fundamental","pubTime":"2025-11-27 10:16","pubTimestamp":1764209811,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  was granted a Family 4 patent by the Hong Kong Special Administrative Region for its anti-infectives, according to a Thursday Australian bourse filing.The patent, expiring in 2041, relates to the process for preparation of the anti-infectives, as well as the use of its R327 and R529 therapy candidates, particularly in the treatment of bacterial infections and viral infections.It also relates to the administration of the anti-infectives by oral, inhalation, transdermal delivery, or by injection. They can also be delivered as an aerosol, gel, topical foam, or ointment.The firm's shares jumped 6% in recent trading on Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2586286421","title":"Recce Pharmaceuticals Says Hospital/Ventilator-Acquired Pneumonia Study in Mice Shows Antibacterial Activity of R327 Therapy Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2586286421","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586286421?lang=en_us&edition=fundamental","pubTime":"2025-11-26 09:57","pubTimestamp":1764122240,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals (ASX:RCE) said its R327 therapy candidate showed antibacterial activity against multidrug-resistant Acinetobacter baumannii in a study of the therapeutic efficacy of R327 in a va","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2581719236","title":"Recce Receives 'First Strike' Against Remuneration Report; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581719236","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581719236?lang=en_us&edition=fundamental","pubTime":"2025-11-05 12:42","pubTimestamp":1762317776,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  received its \"first strike\" against its remuneration report during its annual general meeting on Wednesday.Of the total number of votes cast, over 19% of the votes were in favor of the executive pay report, while nearly 81% were against it, a same-day filing with the Australian bourse showed.More than 25% of shareholders' votes cast against a remuneration report resolution makes a \"strike,\" according to the Corporations Act of 2001.Shares of the company were up nearly 3% in recent Wednesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2570056420","title":"Recce Pharmaceuticals Commences Phase 3 Trial of Topical Gel for Diabetic Foot Infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2570056420","media":"Small Caps","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570056420?lang=en_us&edition=fundamental","pubTime":"2025-09-25 10:43","pubTimestamp":1758768202,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals has commenced patient dosing for a registrational Phase 3 clinical trial of its RECCE 327 topical gel  to treat diabetic foot infections .The company has activated five clinical study sites across one of the world’s largest DFI patient populations in Indonesia, where estimates place the prevalence of diabetes at 20.9 million adults or approximately 11.3% of the nation’s adult population.Recce expects to meet a “highly statistically-significant positive endpoint” after the dosing the first 155 patients in the Phase 3 trial, which the Indonesian and Australian governments as well as Indonesian biomedical collaborator PT Etana are supporting.Up to 310 patients in the randomised trial will receive either R327G or placebo, with the primary objective of assessing clinical responses according to the Lipsky Scale, which the US Food and Drug Administration  recognises as a valid and reliable method for evaluating DFI treatment outcomes.Secondary endpoints include a DFI tot","market":"nz","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/09/Recce-Pharmaceutical-ASX-RCE-Phase-3-Trial-opical-Gel-Diabetic-Foot-Infections.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/09/Recce-Pharmaceutical-ASX-RCE-Phase-3-Trial-opical-Gel-Diabetic-Foot-Infections.jpg"],"rights":{"source":"smallcap_stock","url":"https://smallcaps.com.au/recce-pharmaceuticals-commences-phase-3-trial-topical-gel-diabetic-foot-infections/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/recce-pharmaceuticals-commences-phase-3-trial-topical-gel-diabetic-foot-infections/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2563041579","title":"BRIEF-Recce Pharmaceuticals Reports FY Net Loss Attributable A$21.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2563041579","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563041579?lang=en_us&edition=fundamental","pubTime":"2025-08-29 18:31","pubTimestamp":1756463511,"startTime":"0","endTime":"0","summary":"BRIEF-Recce Pharmaceuticals Reports FY Net Loss Attributable A$21.4 MillionAug 29 (Reuters) - Recce Pharmaceuticals Ltd RCE.AX:FY NET LOSS ATTRIBUTABLE A$21.4 MILLIONFurther company coverage: RCE.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nFWN3UL06O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2563043806","title":"Recce Pharmaceuticals Ltd - FY Net Loss Attributable a$21.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2563043806","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563043806?lang=en_us&edition=fundamental","pubTime":"2025-08-29 17:28","pubTimestamp":1756459732,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nFWN3UL06O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}]}}